PCSK9 Inhibitors

descriptionPublicationkeyboard_double_arrow_right Article 01 May 2016 English Publisher:Elsevier BVJournal:Cell, volume 165, page 1,037 (issn: 0092-8674,

Copyright policy )

Authors: Pradeep, Natarajan; Sekar, Kathiresan;

doi: 10.1016/j.cell.2016.05.016

pmid: 27203103

PCSK9 Inhibitors

- Summary
- Subjects
- Metrics

Abstract

Alirocumab and evolocumab are monoclonal antibodies that block proprotein convertase subtilisin/kexin type 9 (PCSK9), a circulating protein that degrades low-density lipoprotein (LDL) receptors. These therapies increase LDL receptors on the cell surface and reduce plasma LDL cholesterol. Both therapies are approved to lower LDL cholesterol, a causative agent for atherosclerotic cardiovascular disease.

Related Organizations

Massachusetts General Hospital
United States
Broad Institute
United States
Harvard University
United States

Keywords

Anticholesteremic Agents, Antibodies, Monoclonal, Humans, Cholesterol, LDL, Antibodies, Monoclonal, Humanized

Impact byBIP!

	selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	29
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Top 10%
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Top 10%
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Top 10%